Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

Merck & Co., Inc. recently reported robust earnings, yet the market response was lukewarm. Investors overlooked several positive aspects beneath the surface. Unusual expenses, totaling US$4.2 billion, ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...

Merck KGaA is in the investment-grade market Tuesday, a day after holding investor calls, to help fund its $3.9 billion ...

Merck in 2019 inked a deal to evaluate the combination of its blockbuster cancer drug Keytruda with Pacdev from Astellas and Seagen, which Pfizer acquired in a $43 billion deal that closed in late ...

Merck Foundation and Ministry of Gender Equality of Mauritius Train the Journalists to Raise Awareness on Sensitive Social and Health Issues ...

Senator Dr. Rasha Kelej emphasized the critical role that journalists, media professionals, and storytellers play in shaping ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Merck has announced the acquisition of SpringWorks, which is expected to close this year, for an enterprise value of EUR 3 billion. While the deal appears expensive at an 18 times price/sales multiple ...

German drugmaker Merck KGaA on Thursday joined peers in saying it was considering distribution models that serve U.S.

Germany's Merck KGaA raised its full-year guidance for growth in underlying earnings, thanks to better prospects for its life-sciences and healthcare segments, but turned more cautious on sales.